Inhibition of ileal bile acid transporter: An emerging therapeutic strategy for chronic idiopathic constipation

Paula Mosińska, Jakub Fichna, Martin Storr

Abstract

Chronic idiopathic constipation is a common disorder of the gastrointestinal tract that encompasses a wide profile of symptoms. Current treatment options for chronic idiopathic constipation are of limited value; therefore, a novel strategy is necessary with an increased effectiveness and safety. Recently, the inhibition of the ileal bile acid transporter has become a promising target for constipation-associated diseases. Enhanced delivery of bile acids into the colon achieves an accelerated colonic transit, increased stool frequency, and relief of constipation-related symptoms. This article provides insight into the mechanism of action of ileal bile acid transporter inhibitors and discusses their potential clinical use for pharmacotherapy of constipation in chronic idiopathic constipation.

Key words: Bile acids; Chronic idiopathic constipation; Ileal bile acid transporter

© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: Increasing the delivery of bile acids to the colon is considered one of the most promising treatment approaches for patients with constipation. This review discusses recent advances in the field of inhibitors of bile acid transporters and future perspectives in their clinical use.

Mosińska P, Fichna J, Storr M. Inhibition of ileal bile acid transporter: An emerging therapeutic strategy for chronic idiopathic constipation. World J Gastroenterol. 2015 June 28; 21(24): 7436-7442  Available from: URL: http://www.wjgnet.com/1007-9327/full/v21/i24/7436.htm DOI: http://dx.doi.org/10.3748/wjg.v21.i24.7436
INTRODUCTION

Chronic idiopathic constipation (CIC) and constipation-predominant irritable bowel syndrome (IBS-C) are common motility disorders of the lower gastrointestinal tract. CIC occurs in 2%-28% of the population worldwide[1], whereas the overall prevalence of IBS is estimated at approximately 12%-20%[2,3]. CIC and IBS are more commonly reported in women rather than men; however, functional constipation appears to become more frequent with age, and is primarily found in patients over 65 years, while IBS mostly affects people younger than 50 years of age.

The symptoms of CIC and IBS-C are diverse; however, a wide range of gastrointestinal symptoms in CIC overlap with those reported by IBS-C patients and include bloating, infrequent bowel movements, and abdominal pain and/or discomfort[4,5]. Additionally, recent studies demonstrate that incomplete emptying, painful defecation, straining, and hard and lumpy stools are the chief complaints among CIC patients[6,7]. Of note, the major factors distinguishing between CIC and IBS-C are the severity and nature of the abdominal pain[8]. Although the symptoms of CIC and IBS-C are not life threatening, their chronic nature may cause considerable morbidity and can deteriorate the patient’s quality of life.

Currently available pharmacologic treatments for CIC and IBS-C are directed mainly towards increasing fecal residue and stimulating colon activity, and include laxatives, prokinetics, secretagogues, and bile acid (BA) modulators (Table 1). Consequently, reduced visceral sensitivity/pain and improved peristalsis in the upper and lower gastrointestinal tract are observed[9,10,13,16]. Unfortunately, these treatment options are often of limited efficacy, and according to Johanson et al[30], approximately 50% of patients are not satisfied with their constipation therapies. Thus, a novel therapeutic strategy is urgently needed. Increasing the delivery of BAs to the colon is considered one of the most promising treatment approaches for patients with constipation[33].

ILEAL BA TRANSPORTER AS PHARMACOLOGIC TARGET IN CONSTIPATION

BAs are synthesized in the liver through hydroxylation and conjugation of cholesterol to chenodeoxycholic acid (CDCA) and cholic acid. Their biosynthetic pathway includes a series of enzymatic conversions initiated by cholesterol-7α-hydroxylase, which simultaneously constitutes a rate-limiting factor (Figure 1). The rate of hepatic BA synthesis in humans is reflected by the measurement of serum concentrations of the nonspecific marker 7α-hydroxy-4-cholesten-3-one (C4)[11].

Enterohepatic circulation (EHC) is an important mechanism responsible for the movement of BA molecules from the liver to the small intestine and back to the liver. EHC of BAs depends on absorption of BA in the terminal ileum and colon. Once synthesized, BAs are secreted from the hepatocytes into the canalicular tube and traverse through the biliary tract into the intestine, where they play a crucial role in absorption and solubilization of cholesterol, dietary lipids, and fat-soluble vitamins[36]. Some BAs are reabsorbed via a passive mechanism, mostly in the upper intestine. However, almost 95% are reclaimed by the ileal BA transporter (IBAT), also known as apical sodium-dependent BA transporter, abundantly expressed in the terminal ileum[8,10,13,36]. This sodium- and potential-driven transporter reabsorbs BAs from the lumen of the intestine through the apical brush border membrane[12]. This mechanism is considered a major determinant of BA pool size in the human body and is an essential regulator of lipid and cholesterol homeostasis. BAs are then recycled back into the liver via the portal vein for their resecretion into bile, which constitutes the final step of the EHC.

The equilibrium between BA synthesis, secretion, and intestinal reabsorption is vital for the maintenance of important physiologic processes, especially in the case of colonic secretion and motility. Wong et al[11] found a correlation between BA synthesis and constipation, which results from the reduction of hepatic BA synthesis and lower stool BA excretion. Furthermore, mutations in the IBAT gene (SLC10A2) contribute to the disruption of EHC caused by BA malabsorption, in which congenital diarrhea, steatorrhea, and low level of plasma cholesterol are present[12,13]. The same effect of malabsorption was also observed in IBAT-knockout mice[32]. Hence, a number of studies targeted impaired IBAT reabsorption due to its role in colonic transit and its considerable contribution to the effectiveness of the treatment of constipation[11].

Inhibition of IBAT results in a reduction of ileal BA reabsorption, therefore, the concentration of BAs in the proximal colon is increased, similar to the infusion of both conjugated and non-conjugated BAs into the colon. This promotes intracolonic secretion via several mechanisms, including intracellular activation of secretory mechanisms, e.g., adenylate cyclase, enhancement of mucosal permeability[14], and inhibition of apical Cl-/OH- exchange[15]. A study by Bampton et al[16] revealed a twofold increase in proximal colonic propagating sequence frequency in healthy volunteers after administration of 1 mmol of CDCA. Moreover, administration of CDCA in patients with chronic constipation, at dosages of 750-1000 mg/day, resulted in an increase of bowel movements, decrease in stool consistency, and shortened period of fecal excretion[18,20]. Treatment with sodium chenodeoxycholate at a low dosage of 0.5-1.0 g/d also ameliorated colonic transit, and enabled frequent defecation in healthy volunteers.
Elobixibat (former name: A3309) is a novel and promising approach in the treatment of constipation. Elobixibat inhibits ileal BA reuptake via the inhibition of IBAT; during this process, the hepatic synthesis of BA is upregulated on account of the maintenance of EHC homeostasis. Interestingly, the abundant synthesis of cholesterol derivatives leads to the depletion of cholesterol stores in the liver, which simultaneously stimulates the expression of low-density lipoprotein (LDL) receptors on hepatocytes and reduces the level of serum LDL\(^{37}\).

A recent phase I randomized trial showed acceleration of colonic transit, reductions of total plasma cholesterol and LDL by 11% and 16%, respectively, and an increase in the plasma C4 levels in CIC patients after 14 d of treatment with 10 mg of elobixibat. Moreover, a double-blind, placebo-controlled, single-center clinical trial conducted by Simrén et al.\(^{29}\) reported that there were no side effects after its administration. It was suggested that a higher dose of elobixibat may be incorporated into the treatment; however, an overdose of elobixibat may lead to excessive colonic motility, resulting in diarrhea.

Similar favorable therapeutic effects of elobixibat, and patients with ailments related to constipation\(^{18,20}\). Finally, it has been suggested that high luminal accumulation of selected BAs may produce a laxative effect, generally by the stimulation of its prosecretory and promotility actions\(^{8,11,33,38}\).

**CURRENTLY AVAILABLE IBAT INHIBITORS**

Elobixibat (former name: A3309) is a novel and promising approach in the treatment of constipation. Elobixibat inhibits ileal BA reuptake via the inhibition of IBAT; during this process, the hepatic synthesis of BA is upregulated on account of the maintenance of EHC homeostasis. Interestingly, the abundant synthesis of cholesterol derivatives leads to the depletion of cholesterol stores in the liver, which simultaneously stimulates the expression of low-density lipoprotein (LDL) receptors on hepatocytes and reduces the level of serum LDL\(^{37}\).

A recent phase I randomized trial showed acceleration of colonic transit, reductions of total plasma cholesterol and LDL by 11% and 16%, respectively, and an increase in the plasma C4 levels in CIC patients after 14 d of treatment with 10 mg of elobixibat. Moreover, a double-blind, placebo-controlled, single-center clinical trial conducted by Simrén et al.\(^{29}\) reported that there were no side effects after its administration. It was suggested that a higher dose of elobixibat may be incorporated into the treatment; however, an overdose of elobixibat may lead to excessive colonic motility, resulting in diarrhea.

Similar favorable therapeutic effects of elobixibat,
Additionally, administered orally for 14 d, were shown by Wong et al [37] in a phase IIa, single-center, randomized, double-blind, placebo-controlled trial. Overall colonic transit in CIC patients was significantly accelerated at 24 h and 48 h in comparison with the placebo group. Both doses tested, 15 mg and 20 mg, were well tolerated and produced alteration in stool consistency, ease of passage and straining, and an increase in the frequency of spontaneous bowel movements, but no increase in stool frequency. No significant ameliorations were detected regarding abdominal bloating and discomfort. After the treatment with elobixibat, only 4/11 patients in the 15 mg group, and 6/12 patients in the 20 mg group experienced mild to moderate abdominal cramps and pain.

A recent placebo-controlled, phase IIb clinical trial in 190 CIC patients evaluated the efficacy and safety of elobixibat at three doses [38]. The IBAT inhibitor significantly increased bowel movements at 10 mg and 15 mg, but not 5 mg, and led to an alleviation of constipation-associated symptoms, such as straining, bloating, and increased stool consistency. The majority of patients in the 10 mg and 15 mg groups manifested an increase in bowel movements within 24 h of the initial treatment. Moreover, the effect of elobixibat was maintained up to 8 wk after administration. As expected, an increased C4 value, which is an intermediate plasma marker in BA synthesis, was documented. Furthermore, consistent with increased BA synthesis, the total plasma and LDL cholesterol levels were diminished [38]. It was also revealed that the most common side effects, such as abdominal pain/discomfort and diarrhea, were associated most commonly with the 15 mg group. Moreover, the 10 mg dose of elobixibat offered the best efficacy-to-safety ratio, which may be suited for individual treatment in functional constipation. Interestingly, three large, randomized, multicenter phase III trials, ECHO1 (ClinicalTrials.gov identifier: NCT01827592), ECHO2 (ClinicalTrials.gov identifier: NCT01833065) and ECHO3 (ClinicalTrials.gov identifier: NCT01895543), are anticipated to assess the safety and efficacy of elobixibat within a period of 26 wk, 12 wk, and 52 wk, respectively, with the outcomes expected to appear by the end of 2014. Overall, long-term beneficial effects in patients with CIC need to be evaluated, and further studies designed to address the potential of elobixibat are warranted.

**Figure 1** Effect of ileal bile acid transporter in the proximal ileum. BA synthesis is a major metabolic pathway for catabolism of cholesterol. Primary BAs, CA and CDCA, are obtained via the alternative (acidic) pathway, initiated by mitochondrial CYP27A1, or by the classical (neutral) biosynthetic pathway, catalyzed by microsomal CYP7A1. CYP7A1 is a rate-limiting enzyme that regulates the overall rate of BA synthesis in the liver. The activity of CYP7A1 depends upon the quantity of BAs absorbed in the intestine. Inhibition of IBAT contributes to upregulation of BA synthesis and therefore promotes the maintenance of BA pool size. Simultaneously, a decrease in the concentration of serum LDL and an increase of C4 level, which is a surrogate for CYP7A1 activity, may occur. BACS and BAT are two key enzymes involved in the conjugation of BA to amino acids (G or T). In the intestine, conjugated G/T-CDCA and G/T-CA are dehydroxylated to the secondary BAs, DCA and LCA. The action of a selective IBAT inhibitor increases the concentration of BAs entering the proximal colon, which in turn stimulates colonic motility and secretion resulting in enhanced laxative properties. BA: Bile acid; BACS: Bile acid CoA synthase; BAT: Bile acid amino acid transferase; CA: Cholic acid; CDCA: Chenodeoxycholic acids; CYP27A1: Sterol 27 hydroxylase; CYP7B1: Nonspecific 7α-hydroxylase; DCA: Deoxycholic acid; G: Glycine; IBAT: Ileal bile acid transporter; LCA: Lithocholic acid; LDL: Low-density lipoprotein; T: Taurine. Modified from [34-37].
CONCLUSION AND FURTHER PERSPECTIVES

Inhibition of IBAT constitutes a promising novel approach in the treatment of constipation. The only IBAT inhibitor currently available, elobixibat, exerts prokinetic and prosecretory effects in the colon by enhanced BA synthesis and has been shown effective in CIC patients\(^{[40]}\). The applicability of elobixibat in IBS-C remains questionable, and its effects on sensory symptoms still require additional investigation.

Of note, a large body of data indicate that fecal levels of secondary BAs are significantly greater among patients with colorectal adenoma and colorectal cancer\(^{[40-42]}\). Moreover, it was shown that deoxycholic acid (DCA) and lithocholic acid may indirectly promote carcinogenesis by modulating intracellular signaling, e.g., via induction of cyclooxygenase-2, secretion of matrix metalloproteinase-2, or activation of plasma membrane muscarinic and epidermal growth factor receptors that lead to alterations in gene expression and stimulate colon cancer proliferation\(^{[43,44]}\). Exposure of rodent colonic mucosa cells or human adenocarcinoma cell lines, such as HCT-116 and CaCo-2, to BAs stimulates the production of reactive oxygen species, which consequently can result in gene mutation and constitutive activation of prosurvival stress-response pathways\(^{[45]}\). In line with this, DCA administration in a rat model of colonic carcinogenesis enhances the incidence of K-ras point mutation and proliferation in colon tumors\(^{[46]}\). Additionally, Qiao et al\(^{[47]}\) showed the correlation between tumor-promoting BA DCA and the tumor suppressor gene p53, resulting in the inhibition of p53 response to genotoxic compounds in the colon, which ultimately enhances mutagenesis and can increase the risk of cancer. An investigation by Little et al\(^{[48]}\), which was based on subjects with asymptomatic cancer and adenomatous polyps, found a relationship between an increased concentration of major BAs and villus adenomas; nonetheless, the risk of large adenomas or colorectal cancer did not correlate with elevated fecal BA concentration. Similar outcomes were obtained in a cohort study by Haines et al\(^{[49]}\), where there were no significant differences between the left-sided bowel cancer and control groups for any of the concentrations of individual BAs, total BA concentrations, fecal-neutral steroids, percentage bacterial conversion, or the ratio of lithocholic acid to DCA concentrations. A weak correlation between CDCA in feces and the risk of right-sided bowel cancer were reported; however, it was postulated that other factors such as genetic predisposition were also involved in the development of large bowel cancer.

Elobixibat is a relatively new drug and only a limited number of studies are available. Thus, in order to comprehensively evaluate the risk and benefit profiles of this IBAT inhibitor, a meta-analysis is desirable, especially in terms of cancer related-issues and possibility of treatment of IBS-C. On the other hand, development of novel IBAT inhibitors with a modified pharmacologic profile and bioavailability could provide drug candidates with a favorable endpoint and no adverse effects. Yet another possibility is to encourage research on other signaling pathways that involve a distinct BA transporter that is not involved in tumor progression.

To conclude, further meticulous studies are needed to facilitate the development of optimal chemoprotective strategies for the treatment of constipation.

REFERENCES

1. Shahid S, Ramzan Z, Maurer AH, Parkman HP, Fisher RS. Chronic idiopathic constipation: more than a simple colonic transit disorder. J Clin Gastroenterol 2012; 46: 150-154 [PMID: 22011587 DOI: 10.1097/MCG.0b013e318231f664]
2. Dai C, Zheng CQ, Jiang M, Ma XY, Jiang LJ. Probiotics and irritable bowel syndrome. World J Gastroenterol 2013; 19: 5973-5980 [PMID: 24106397 DOI: 10.3748/wjg.v19.i36.5973]
3. Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol 2012; 10: 712-721.e4 [PMID: 22426087 DOI: 10.1016/j.cgh.2012.02.029]
4. Andrensen V, Camilleri M, Busciglio IA, Grudell A, Burton D, McKenzie S, Foxx-Orenstein A, Kurtz CB, Sharma V, Johnston JM, Currie MG, Zinsmeister AR. Effect of 5 days linaclotide on transition and bowel function in females with constipation-predominant irritable bowel syndrome. Gastroenterology 2007; 133: 761-768 [PMID: 17854590]
5. Frissora CL, Koch KL. Symptom overlap and comorbidity of irritable bowel syndrome with other conditions. Curr Gastroenterol Rep 2005; 7: 264-271 [PMID: 16042909 DOI: 10.1007/s11894-005-0018-9]
6. Liu J, Hou X. A review of the irritable bowel syndrome investigation on epidemiology, pathogenesis and pathophysiology in China. J Gastroenterol Hepatol 2011; 26 Suppl 3: 88-93 [PMID: 21443718 DOI: 10.1111/j.1440-1746.2011.06641.x]
7. Schoenfeld PS. New treatment option for irritable bowel syndrome with constipation and chronic idiopathic constipation. Gastroenterol Hepatol (N Y) 2012; 8: 825-828 [PMID: 24693271]
8. Bajor A, Gillberg PG, Abrahamsson H. Bile acids: short and long term effects in the intestine. Scand J Gastroenterol 2010; 45: 645-664 [PMID: 20334475 DOI: 10.3109/00365521003702734]
9. Mozaffari S, Nikfar S, Abdollahi M. The safety of novel drugs used to treat irritable bowel syndrome. Expert Opin Drug Saf 2014; 13: 625-638 [PMID: 24669839 DOI: 10.1517/14740338.2014.902932]
10. Trauner M, Boyer JL. Bile salt transporters: molecular characterization, function, and regulation. Physiol Rev 2003; 83: 633-671 [PMID: 12663868 DOI: 10.1152/physrev.00027.2002]
11. Wong BS, Camilleri M, Carlson P, McKenzie S, Busciglio I, Bondar O, Dyer RB, Lamsam J, Zinsmeister AR. Increased bile acid biosynthesis is associated with irritable bowel syndrome with diarrhea. Clin Gastroenterol Hepatol 2012; 10: 1009-15.e3 [PMID: 22616000 DOI: 10.1016/j.cgh.2012.05.006]
12. Dawson PA, Haywood J, Craddock AL, Wilson M, Tietjen M, Kluckman K, Maeda N, Parks JS. Targeted deletion of the ileal bile acid transporter eliminates enterohepatic cycling of bile acids in mice. J Biol Chem 2003; 278: 33920-33927 [PMID: 12819193 DOI: 10.1074/jbc.M306370200]
13. Jung D, Fantin AC, Scheuer U, Fried M, Kullak-Ublick GA. Human ileal bile acid transporter gene ASBT (SLC10A2) is transactivated by the glucocorticoid receptor. Gut 2004; 53: 78-84 [PMID: 14684580 DOI: 10.1136/gut.53.1.78]
14. Raimondi F, Santoro P, Barone MV, Papaccio S, Barretta ML,
Nanayakkara M, Apicella C, Capasso L, Paludetto R. Bile acids modulate tight junction structure and barrier function of Caco-2 monolayers via EGFR activation. *Am J Physiol Gastrointest Liver Physiol* 2008; 294: G906-G913 [PMID: 18239063 DOI: 10.1152/ajpgi.00043.2007].

15 Alrefai WA, Saksena S, Tyagi S, Gill RK, Ramswamy K, Dudeja PK. Taurodeoxycholate modulates apical Cl-/OH- exchange activity in Caco2 cells. *Dig Dis Sci* 2007; 52: 1270-1278 [PMID: 17387613 DOI: 10.1016/j.tds.2006-09-0900-8].

Bampton PA, Dinning PG, Kennedy ML, Lubowski DZ, Cook JJ. The proximal colonic motor response to rectal mechanical and chemical stimulation. *Am J Physiol Gastrointest Liver Physiol* 2002; 282: G43-G44 [PMID: 11841994 DOI: 10.1152/ajpgi.00194.2001].

17 Gonzalez-Martínez MA, Ortiz-Olvera NX, Méndez-Navarro J. Novel pharmacological therapies for management of chronic constipation. *J Clin Gastroenterol* 2014; 48: 21-28 [PMID: 24172177 DOI: 10.1097/MJC.0b013e3182a9c24f].

18 Rao AS, Wong BS, Camilleri M, Odunsi-Shiyanbade ST, McKinzie S, Ryks M, Burton D, Carlson P, Lamsam J, Singh R, Zinsmeister AR. Cholesterol metabolism in females with irritable bowel syndrome: a pharmacodynamic and pharmacogenetic analysis. *Gastroenterology* 2010; 139: 1549-1558, 1558.e1 [PMID: 20691689 DOI: 10.1053/j.gastro.2010.07.052].

19 Sood R, Ford AC. Linacolide: new mechanisms and new promise for treatment in constipation and irritable bowel syndrome. *Ther Adv Chronic Dis* 2013; 4: 268-276 [PMID: 24176969 DOI: 10.1177/20462231350110].

20 Odunsi-Shiyanbade ST, Camilleri M, McKinzie S, Burton D, Carlson P, Busciglio IA, Lamsam J, Singh R, Zinsmeister AR. Effects of chenodeoxycholate and a bile acid sequestrant, colesevolam, on intestinal transit and bowel function. *Clin Gastroenterol Hepatol* 2010; 8: 159-165 [PMID: 19879973 DOI: 10.1016/j.cgh.2009.10.020].

21 Lembo AJ, Cremonini F, Meyers N, Hickling R. Clinical trial: renzapride treatment of women with irritable bowel syndrome and constipation - a double-blind, randomized, placebo-controlled, study. *Aliment Pharmacol Ther* 2010; 31: 979-990 [PMID: 20163375 DOI: 10.1111/j.1365-2036.2010.04265.x].

22 Spiller RC, Meyers NL, Hickling RI. Identification of patients with non-d, non-C irritable bowel syndrome and treatment with renzapride: an exploratory, multicenter, randomized, double-blind, placebo-controlled clinical trial. *Dis Colo Rect* 2008; 53: 3191-3200 [PMID: 18465259 DOI: 10.1007/s10620-008-0295-x].

23 Manini ML, Camilleri M, Goldberg M, Sweetser S, McKinzie S, Burton D, Longo S, Kitt MM, Li YP, Zinsmeister AR. Effects of Velusetrag (TD-5108) on gastrointestinal transit and bowel function in health and pharmacokinetics in health and constipation. *Neurogastroenterol Motil* 2010; 22: 42-9, e7-8 [PMID: 19691492 DOI: 10.1111/j.1365-2982.2009.01378.x].

24 Goldberg M, Li YP, Johanson JF, Mangel AW, Kitt M, Beattie DT, Kersey K, Daniels O. Clinical trial: the efficacy and tolerability of velusetrag, a selective 5-HT4 agonist with high intrinsic activity, in chronic idiopathic constipation - a 4-week, randomized, double-blind, placebo-controlled, dose-response study. *Aliment Pharmacol Ther* 2010; 32: 1102-1112 [PMID: 21039672 DOI: 10.1111/j.1365-2036.2010.04456.x].

25 Camilleri M, Vázquez-Roque MI, Burton D, Ford T, McKinzie S, Zinsmeister AR. Drug-induced constipation and detoxification of its use in the management of irritable bowel syndrome with constipation. *Expert Rev Gastroenterol Hepatol* 2011; 5: 657-659 [PMID: 22017692 DOI: 10.1586/egh.11.63].

26 Li T, Chiang JY. Nuclear receptors in bile acid metabolism. *Drug Metab Rev* 2013; 45: 145-155 [PMID: 23330546 DOI: 10.1093/dmr/dbt003].

27 Patti MN, Walters JR. Recent advances in the understanding of bile acid malabsorption. *Br Med Bull* 2009; 92: 79-93 [PMID: 19009047 DOI: 10.1093/bmb/lip032].

28 Reshetnyak VI. Physiological and molecular biochemical mechanisms of bile formation. *World J Gastroenterol* 2013; 19: 7341-7360 [PMID: 24225965 DOI: 10.3748/wjg.v19.i42.7341].

29 Wong BS, Camilleri M, McKinzie S, Burton D, Graffner H, Zinsmeister AR. Effects of A3309, an ileal bile acid transporter inhibitor, on colonic transit and symptoms in females with functional constipation. *Am J Gastroenterol* 2011; 106: 2154-2164 [PMID: 21876564 DOI: 10.1038/ajg.2011.285].

30 Chey WD, Camilleri M, Chang L, Rinkler L, Graffner H. A randomized placebo-controlled phase IIb trial of A3309, a bile acid transporter inhibitor, for chronic idiopathic constipation. *Am J Gastroenterol* 2011; 106: 1803-1812 [PMID: 21606974 DOI: 10.1038/ajg.2011.162].

31 Simrén M, Bajor A, Gillberg PG, Rudling M, Abrahamsson H. Randomised clinical trial: the ileal bile acid transporter inhibitor A3309 vs. placebo in patients with chronic idiopathic constipation - a double-blind study. *Aliment Pharmacol Ther* 2011; 34: 41-50 [PMID: 21545606 DOI: 10.1111/j.1365-2036.2011.04675.x].

32 Acosta A, Camilleri M. Elobixibat and its potential role in chronic idiopathic constipation. *Ther Adv Gastroenterol* 2014; 7: 167-175 [PMID: 25057297 DOI: 10.1177/1756283X14528269].

33 Ochsenhünn K, Bayerdörffer E, Meining A, Schinkel M, Thiede C, Nüsser V, Sackmann M, Hatz R, Neubauer A, Paumgartner G. Colon mucosal proliferation is related to serum deoxycholic acid levels. *Cancer* 1999; 85: 1664-1669 [PMID: 10223558].

34 Tong JI, Ran ZH, Shen J, Fan GQ, Xiao SD. Association between fecal bile acids and colorectal cancer: a meta-analysis of observational studies. *Yonsei Med J* 2008; 49: 792-803 [PMID: 18972600 DOI: 10.3349/ymj.2008.49.4.792].

35 Cheng K, Raunig JP. Bile acid-induced proliferation of a human colon cancer cell line is mediated by transactivation of epidermal growth factor receptors. *Biochem Pharmacol* 2005; 70: 1035-1047 [PMID: 16139803 DOI: 10.1016/j.bcp.2005.07.023].

36 Raunig JP, Cheng K, Zimmnik P. Activation of muscarinic receptor signaling by bile acids: physiological and medical implications. *Dig Dis Sci* 2003; 48: 1431-1444 [PMID: 12924634].

37 Payne CM, Söder MG, Crowe S, Kramer A, Dvorakova D, Bernstein H, Bernstein C, Holubec H, Dvorakova B, Garewal H. Deoxycholate induces mitochondrial oxidative stress and activates NF-kappaB through multiple mechanisms in HCT-116 colon epithelial cells. *Carcinogenesis* 2007; 28: 215-222 [PMID: 16887864 DOI: 10.1093/carcin/bgl139].

38 Narahara H, Tatsuta M, Iishi H, Baba M, Uedo N, Sakai N, Yano H, Ishiguro S. K-ras point mutation is associated with

Mosińska P et al. Inhibition of ileal bile acid transporter
Mosińska P et al. Inhibition of ileal bile acid transporter

enhancement by deoxycholic acid of colon carcinogenesis induced by azoxymethane, but not with its attenuation by all-trans-retinoic acid. *Int J Cancer* 2000; 88: 157-161 [PMID: 11004662 DOI: 10.1002/1097-0215(20001015)88]

47 Qiao D, Gaitonde SV, Qi W, Martinez JD. Deoxycholic acid suppresses p53 by stimulating proteasome-mediated p53 protein degradation. *Carcinogenesis* 2001; 22: 957-964 [PMID: 11375905 DOI: 10.1093/carcin/22.6.957]

48 Little J, Owen RW, Fernandez F, Hawtin PG, Hill MJ, Logan RF, Thompson MH, Hardcastle JD. Asymptomatic colorectal neoplasia and fecal characteristics: a case-control study of subjects participating in the nottingham fecal occult blood screening trial. *Dis Colon Rectum* 2002; 45: 1233-1241 [PMID: 12352242 DOI: 10.1007/s10350-004-6398-3]

49 Haines A, Hill MJ, Thompson MH, Owen RW, Williams RE, Meade TW, Wilkes H, Griffin M. A prospective study of faecal bile acids and colorectal cancer. *Eur J Cancer Prev* 2000; 9: 317-323 [PMID: 11075884]

P- Reviewer: Nishida T, Soylu OB  S- Editor: Qi Y  L- Editor: AmEditor  E- Editor: Ma S
